Short-Term Efficacy and Safety of Camrelizumab-Based Treatment for Refractory or Metastatic Oesophageal Squamous Cell Carcinoma
Yuan Yuan1, Qingliang Meng1, Liang Han1, Yu Feng1, Xiaowu Li11Department of Medical Oncology, Xuzhou Central Hospital, Xuzhou, China,
Objectives: To evaluate the shortterm efficacy and safety of camrelizumab in combination with apatinib for refractory or metastatic oesophageal squamous cell carcinoma. Methods: We retrospectively reviewed the medical records of 30 patients with refractory or metastatic oesophageal squamous cell carcinoma treated with camrelizumab in combination with apatinib at a single institution. The shortterm efficacy was evaluated according to the RECIST. The safety was evaluated by the CTCAE. Results: Among all 30 patients, the ORR and DCR were 27% (8/30) and 63% (19/30), respectively. CR was achieved in 0% (0/30) of patients, PR in 27% (8/30), SD in 36% (11/30), and 37% (11/30) experienced PD. The median PFS interval was 3.7 (95% CI: 2.48?3.88) months, and the median OS outcome was not reached. Conclusion: Our study reveals that camrelizumab in combination with apatinib is a promising therapy for patients with refractory or metastatic ESCC. This combination has a high response rate and favourable clinical safety. Keywords: Apatinib, camrelizumab, efficacy, oesophageal squamous cell carcinoma, safety
Cite This Article
Yuan Y, Meng Q, Han L, Feng Y, Li X. Short-Term Efficacy and Safety of Camrelizumab-Based Treatment for Refractory or Metastatic Oesophageal Squamous Cell Carcinoma. EJMO. 2023; 7(3): 265-269
Corresponding Author: Xiaowu Li